Acura Pharmaceuticals Inc. has amended its existing secured promissory note with Abuse Deterrent Pharma, LLC, expanding the total principal amount available under the agreement. The original note, dated November 10, 2022, had a principal of $2,319,279. Subsequent amendments have added a series of additional loans, bringing the aggregated principal to $9,294,279 as of December 12, 2025. The amendment details the schedule of new loans, with individual disbursements of $100,000 each, extending through December 2025. The agreement was executed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-124500), on December 29, 2025, and is solely responsible for the information contained therein.